نتائج البحث - "Bastian von Tresckow"

1

Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

المؤلفون: Aurore Bergamasco, Yola Moride, Wouter J. Plattel, F. Trinchese, Athanasios Zomas, Nawal Bent-Ennakhil, Genaro Castillon, Teigna Arredondo-Bisono, Bastian von Tresckow, François Gavini, Tiffany Cristarella

المصدر: Leukemia & Lymphoma. 62:3320-3332

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ae549228bb5472cb72128bf4a2c02aTest
https://doi.org/10.1080/10428194.2021.1957865Test

2

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

المساهمون: Hematology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life

المصدر: The Lancet Oncology, 22(2), 223-234. Lancet Publishing Group
Borchmann, P, Plütschow, A, Kobe, C, Greil, R, Meissner, J, Topp, M S, Ostermann, H, Dierlamm, J, Mohm, J, Thiemer, J, Sökler, M, Kerkhoff, A, Ahlborn, M, Halbsguth, T V, Martin, S, Keller, U, Balabanov, S, Pabst, T, Vogelhuber, M, Hüttmann, A, Wilhelm, M, Zijlstra, J M, Moccia, A, Kuhnert, G, Bröckelmann, P J, von Tresckow, B, Fuchs, M, Klimm, B, Rosenwald, A, Eich, H, Baues, C, Marnitz, S, Hallek, M, Diehl, V, Dietlein, M & Engert, A 2021, ' PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 223-234 . https://doi.org/10.1016/S1470-2045Test(20)30601-X
Strahlentherapie Und Onkologie

مصطلحات موضوعية: Male, medicine.medical_treatment, Medizin, Procarbazine, Gastroenterology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, 030212 general & internal medicine, 610 Medicine & health, Etoposide, education.field_of_study, Middle Aged, Combined Modality Therapy, Hodgkin Disease, Dacarbazine, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Female, Rituximab, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Population, Vinblastine, Disease-Free Survival, Bleomycin, Young Adult, 03 medical and health sciences, Internal medicine, Mucositis, Humans, education, Cyclophosphamide, Neoplasm Staging, Proportional Hazards Models, Chemotherapy, business.industry, medicine.disease, Regimen, ABVD, Doxorubicin, Positron-Emission Tomography, Prednisone, business, Literatur Kommentiert

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f13d466acfe65ac8d5c77ff231c4382Test
https://doi.org/10.1016/s1470-2045Test(20)30601-x

3

Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study : A report from the German Hodgkin Study Group

المؤلفون: Peter Borchmann, Andreas Rosenwald, Ina Bühnen, Martin-Leo Hansmann, Wolfram Klapper, Bastian von Tresckow, Andreas Engert, Michael Fuchs, Peter Möller, Dennis A. Eichenauer, Helen Goergen, Sylvia Hartmann, Alfred C. Feller, Stefanie Kreissl, Heinz-Wolfram Bernd

وصف الملف: application/octet-stream

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abdc45b77ad5760367b866ffb7ef522Test
https://www.ncbi.nlm.nih.gov/pubmed/34396513Test

4

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

المؤلفون: Bastian von Tresckow, Peter Borchmann, Michael Fuchs, Sylvia Hartmann, Andreas Engert, Martin-Leo Hansmann, Annette Plütschow, Boris Böll, Dennis A. Eichenauer

المصدر: Leukemia. 34:953-956

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, Long term follow up, Phases of clinical research, Hematology, Newly diagnosed, Gastroenterology, language.human_language, German, Oncology, Nodular Lymphocyte Predominant Hodgkin Lymphoma, Internal medicine, medicine, language, Rituximab, Stage (cooking), business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::abada5ad2dfcc370d2157ae69cd7ca58Test
https://doi.org/10.1038/s41375-019-0609-3Test

5

Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

المؤلفون: Bastian von Tresckow, Cyrus Sayehli, Walter E. Aulitzky, Maria-Elisabeth Goebeler, Babett Krauss, Rene Bartz, Rolf Krauss, Eunice Braz, Andreas Engert, Frank Hermann, Matthias Schwab

المصدر: European Journal of Haematology. 102:163-173

مصطلحات موضوعية: Male, medicine.medical_specialty, medicine.drug_class, Drug Evaluation, Preclinical, Gastroenterology, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Cell Line, Tumor, Internal medicine, medicine, Humans, Neoplasm Metastasis, Adverse effect, Neoplasm Staging, Dose-Response Relationship, Drug, business.industry, Histone deacetylase inhibitor, Hematology, General Medicine, medicine.disease, Pulmonary embolism, Histone Deacetylase Inhibitors, Treatment Outcome, Tolerability, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Pharmacodynamics, Benzamides, Cohort, Toxicity, Female, Tomography, X-Ray Computed, business, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ed5d86078a796bbad62a85222f92beTest
https://doi.org/10.1111/ejh.13188Test

6

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

المصدر: Blood. 138:131-131

مصطلحات موضوعية: medicine.medical_specialty, Adult patients, business.industry, Immunology, Follicular lymphoma, Subgroup analysis, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Internal medicine, Relapsed refractory, medicine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5f8aa838fb4add4d926b4460fd144981Test
https://doi.org/10.1182/blood-2021-145025Test

7

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

المؤلفون: Pier Luigi Zinzani, Robert T. Chen, Akihiro Tomita, Vincent Ribrag, Pauline Brice, Theodoros P. Vassilakopoulos, Daniel Molin, Margaret A. Shipp, Craig H. Moskowitz, Arun Balakumaran, Nathalie A. Johnson, Bastian von Tresckow, Hun Ju Lee, Philippe Armand, John Radford, Eunhee Kim, Jianxin Lin, Akash Nahar

المساهمون: Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A, Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P, Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A, Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun, Moskowitz, Craig H

المصدر: Chen, R, Zinzani, P L, Lee, H J, Armand, P, Johnson, N A, Brice, P, Radford, J, Ribrag, V, Molin, D, Vassilakopoulos, T P, Tomita, A, von Tresckow, B, Shipp, M A, Lin, J, Kim, E, Nahar, A, Balakumaran, A & Moskowitz, C H 2019, ' Pembrolizumab in relapsed or refractory Hodgkin lymphoma : 2-year follow-up of KEYNOTE-087 ', Blood, vol. 134, no. 14, pp. 1144-1153 . https://doi.org/10.1182/blood.2019000324Test

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, Immunology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Biochemistry, Gastroenterology, Disease-Free Survival, Pembrolizumab, relapsed, refractory, Hodgkin lymphoma, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Autologous stem-cell transplantation, Antineoplastic Agents, Immunological, Refractory, Internal medicine, medicine, Refractory Hodgkin Lymphoma, Humans, Adverse effect, Brentuximab vedotin, Aged, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cell Biology, Hematology, Middle Aged, medicine.disease, Hodgkin Disease, 030104 developmental biology, Treatment Outcome, Cohort, Female, Neoplasm Recurrence, Local, business, Progressive disease, 030215 immunology, medicine.drug, Follow-Up Studies